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Monophosphoryl lipid A (MPL) is a non-toxic TLR4
ligand, derived from Salmonella minnesota R595 (Re)
lipopolysaccharide (LPS) by chemical modification. It is
clinically used as an adjuvant for cancer treatment (Fen-
drix®, Ceravix®) and allergen specific immunotherapy
(Pollinex® Quattro, ORALVAC®). Nevertheless, reports
on the mechanism of adjuvant activity are limited. The
aim of this study was to compare the immune modulat-
ing capacities of MPL and LPS in vitro.
In both human and murine lung epithelial cell lines
(LA-4, A549) LPS induced a higher CCL2 secretion than
MPL. In murine BM-derived myeloid dendritic cells
(mDC), LPS as well as MPL stimulation resulted in the
same pattern of cytokine secretion (IL-1b, IL-6, IL-10 and
TNF-a). At high concentrations of MPL, IL-1b secretion
was 4-fold higher compared to LPS, whereas LPS stimula-
tion resulted in higher secretion of IL-6, IL-10 and TNF-
a, respectively. Moreover, mDC stimulation with both
adjuvants resulted in a pronounced cell activation pattern
characterized by CD40 and CD69 upregulation, at which
LPS proved to be more potent than MPL (thresholds for
mDC activation: MPL: 100 ng/ml, LPS: 1 ng/ml). In
MyD88-/- and Trif-/- mDC, MPL-induced cytokine secre-
tion was absent in MyD88- but only reduced in Trif-defi-
cient mDC. LPS induced cytokine secretion was mostly
unchanged in Trif-/- mDC. Furthermore, the co-adminis-
tration of MPL and Ova resulted in enhanced IFN-g and
IL-5 secretion from OVA-specific DO11.10 CD4+ T cells
co-cultured with BALB/c mDC which was not observed
for LPS controls. In line with this result, stimulation with
a covalent fusion protein of MPL and Ova (MPL:Ova)
resulted in enhanced cytokine secretion from both mDC
(IL-1b, IL-6, TNF, IL-10, IL-12) and CD4 T cells (IL-5,
IL-13, IL-2, IFN-g, IL-17) compared to equimolar concen-
trations of MPL and Ova provided individually or as a
mixture. Interestingly, Ova induced IL-9 secretion from
CD4+ T cells was dose-dependently repressed when fused
to MPL.
In summary, using in vitro assay systems we observed
similar but attenuated immune responses induced by
MPL in comparison to LPS. MPL applied together with
allergen (either mixed or covalently fused) on CD4+
T cells boosted allergen-specific TH1-, TH2-, and TH17-
adaptive responses. Although considered safe in humans,
further studies should critically assess the adjuvant capa-
city of MPL in order to evaluate potential non-desired
immunological effects.
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